CAMBRIDGE, Mass.--(BUSINESS WIRE)--Unum Therapeutics, a company developing a universal cellular immunotherapy to treat multiple cancers, announced today that it has named Christiana Stamoulis as its Chief Financial Officer and Head of Corporate Development, effective immediately.
Ms. Stamoulis will work closely with Chuck Wilson, PhD, President & CEO of Unum Therapeutics, and Seth Ettenberg, PhD, Chief Scientific Officer, in driving Unum’s financial strategy and in cultivating business development relationships.
“With her broad and deep experience in both multi-billion dollar mergers and acquisitions (M&A) and capital-raising transactions, including taking numerous companies public, Christiana’s skillsets are exactly what we need to accelerate our growth,” said Dr. Wilson. “She is a valuable addition to our executive management team as we seek collaborators for our novel therapy that leverages two of the most promising cancer immunotherapy technologies – engineered T-cells and monoclonal antibodies.”
Ms. Stamoulis has nearly 20 years of experience in the biotechnology industry as a senior executive and a strategic and corporate finance advisor to CEOs and Boards of Directors of global biopharmaceutical companies. She has extensive experience in developing strategies for sustainable growth and executing complex M&A deals, strategic collaborations and capital-raising transactions with aggregate value in excess of $100 billion.
Most recently, Ms. Stamoulis was the Senior Vice President and Head of Corporate Strategy and Business Development at Vertex Pharmaceuticals, where she helped develop the company’s vision and led its efforts to form strategic business collaborations. Prior to Vertex, she was a Managing Director in Citigroup’s Investment Banking division and a senior investment banker at Goldman, Sachs & Co’s Healthcare Investment Banking Group, where she spent the majority of her investment banking career.
Ms. Stamoulis graduated from the MIT Sloan School of Management with a Master degree in Business Administration. She also has Bachelor of Science degrees in Economics and Architecture from the Massachusetts Institute of Technology. She currently serves as a director of the Board of Hologic, a leading global developer and supplier of diagnostic products, medical imaging systems and surgical products.
About Unum Therapeutics
Unum Therapeutics uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body’s own immune system to fight cancer. Unum’s lead program, based on its Antibody-Coupled T-cell Receptor (ACTR) technology, recently entered Phase I clinical testing to assess safety and efficacy. Unum is seeking partners interested in using the ACTR technology to arm proprietary tumor-specific antibodies with a T-cell to improve their therapeutic potential. The company is headquartered in Cambridge, MA. For more information, visit www.unumrx.com.
